Time to revisit some stocks now that biotech has cooled.
The trial enrolled 1,313 RMS patients in 21 countries for two years of study.
Insiders at Twitter, Biogen and three other companies have been snapping up shares of their own stock lately.
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.